Recruiting

Testing different doses of a blood-clotting medication for recent strokes

Plain-English translation of NCT06712004 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called bevifibatide to see if it can help improve recovery after an acute ischemic stroke (a stroke caused by a blood clot). Bevifibatide works by preventing blood platelets from sticking together and forming dangerous clots. The study will compare two different doses of the medication to find which dose is safest and most effective.

Doctors need better treatment options for stroke patients who cannot receive standard clot-busting therapies. This medication has been used for heart problems, but no one has studied the right dose for treating strokes, so this trial will help determine the safest and most effective dose.

Do you qualify?

You likely qualify if…

you have had an acute ischemic stroke (caused by a blood clot) within the last 24 to 96 hours
you are ineligible for standard stroke treatments like intravenous clot-busting therapy or mechanical thrombectomy, or you had a stroke worsen after receiving those treatments
your stroke symptoms are moderate or worse (a NIHSS score of 3 or higher, which is a standard scale doctors use)
brain imaging shows no large or medium blood vessel is completely blocked
you do not have bleeding in the brain, confirmed by CT scan or MRI

You likely don't qualify if…

you have bleeding in the brain
you have a history of brain bleeding, brain aneurysm, or brain tumor
you have a heart condition known to cause blood clots, such as atrial fibrillation or a mechanical heart valve
you have had major bleeding in your stomach, urinary tract, or elsewhere in your body in the last 30 days
you are pregnant or breastfeeding

What participation looks like

If you are eligible, you will be randomly assigned to receive one of two doses of bevifibatide. The medication is given by injection into your vein, starting with a single dose followed by a continuous infusion over 24 hours. The two groups differ only in the rate of the continuous infusion. You will be monitored closely during and after treatment, and your recovery will be assessed at 90 days to measure how well the medication worked and whether it caused any serious side effects like bleeding in the brain.

AI-generated summary from trial data · Jun 1, 2026 · Not medical advice

Trial locations(1 site)

China

Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong